Hypercytotoxicity and Rapid Loss of NKp44+ Innate Lymphoid Cells during Acute SIV Infection

PLoS Pathogens

Volumn 10, Issue 12, 2014, Pages

  Li, Haiying ^a   Richert Spuhler, Laura E ^b   Evans, Tristan I ^c   Gillis, Jacqueline ^c   Connole, Michelle ^c   Estes, Jacob D ^d   Keele, Brandon F ^d   Klatt, Nichole R ^b   Reeves, R Keith ^a,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; GAMMA INTERFERON; INTERLEUKIN 17; KI 67 ANTIGEN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GASTROINTESTINAL TRACT; HYPERCYTOTOXICITY; INNATE IMMUNITY; INTESTINE MUCOSA; LYMPHOID CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; STIMULATION; VIREMIA; VIRUS LOAD;

SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84919608014     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004551     Document Type: Article

References (63)

1. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. (2004) CD4+T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200: 749–759.
2. Sankaran S, Guadalupe M, Reay E, George MD, Flamm J, et al. (2005) Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci U S A 102: 9860–9865.
3. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, et al. (2005) Peak SIV replication in resting memory CD4+T cells depletes gut lamina propria CD4+T cells. Nature 434: 1148–1152.
4. Veazey RS, DeMaria M, Chalifoux LV, Shvetz D, Pauley D, et al. (1998) The gastrointestinal tract as a major site of CD4 T lymphocyte depletion and viral replication in SIV infection. Science 280: 427–431.
5. Haase AT, (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464: 217–223.
6. Mattapallil JJ, Douek DC, Hill BJ, Nishimura Y, Martin M, et al. (2005) Massive infection and loss of memory CD4+T cells in multiple tissues during acute SIV infection. Nature 434: 1093–1097.
7. Veazey RS, Tham IC, Mansfield KG, DeMaria M, Forand AE, et al. (2000) Indentifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4+T cells are rapidly eliminated in early SIV infection in vivo. J Virol 74: 57–64.
8. Spits H, Cupedo T, (2012) Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 30: 647–675.
9. Spits H, Di Santo JP, (2011) The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 12: 21–27.
10. Satoh-Takayama N, Vosshenrich CA, Lesjean-Pottier S, Sawa S, Lochner M, et al. (2008) Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 29: 958–970.
11. Sonnenberg GF, Monticelli LA, Elloso MM, Fouser LA, Artis D, (2011) CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 34: 122–134.
12. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, et al. (2008) Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14: 282–289.
13. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, et al. (2010) Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 463: 540–544.
14. Boos MD, Yokota Y, Eberl G, Kee BL, (2007) Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity. J Exp Med 204: 1119–1130.
15. Schmutz S, Bosco N, Chappaz S, Boyman O, Acha-Orbea H, et al. (2009) Cutting edge: IL-7 regulates the peripheral pool of adult ROR gamma+ lymphoid tissue inducer cells. J Immunol 183: 2217–2221.
16. Satoh-Takayama N, Lesjean-Pottier S, Vieira P, Sawa S, Eberl G, et al. (2010) IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors. J Exp Med 207: 273–280.
17. Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, et al. (2012) The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 36: 55–67.
18. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, et al. (2009) A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457: 722–725.
19. Takatori H, Kanno Y, Watford WT, Tato CM, Weiss G, et al. (2009) Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 206: 35–41.
20. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, et al. (2013) Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol 13: 145–149.
21. Hoyler T, Klose CS, Souabni A, Turqueti-Neves A, Pfeifer D, et al. (2012) The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity 37: 634–648.
22. Mjosberg J, Bernink J, Golebski K, Karrich JJ, Peters CP, et al. (2012) The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 37: 649–659.
23. Reeves RK, Rajakumar PA, Evans TI, Connole M, Gillis J, et al. (2011) Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection. Blood 118: 3321–3330.
24. Xu H, Wang X, Liu DX, Moroney-Rasmussen T, Lackner AA, et al. (2012) IL-17-producing innate lymphoid cells are restricted to mucosal tissues and are depleted in SIV-infected macaques. Mucosal Immunol 5: 658–669.
25. Klatt NR, Estes JD, Sun X, Ortiz AM, Barber JS, et al. (2012) Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol 5: 646–657.
26. Khowawisetsut L, Pattanapanyasat K, Onlamoon N, Mayne AE, Little DM, et al. (2013) Relationships between IL-17(+) subsets, Tregs and pDCs that distinguish among SIV infected elite controllers, low, medium and high viral load rhesus macaques. PLoS One 8: e61264.
27. Liyanage NP, Gordon SN, Doster MN, Pegu P, Vaccari M, et al. (2014) Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac(2)(5)(1) infection of macaques. Virology 450–451: 359–368.
28. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, et al. (2003) Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol 171: 5663–5667.
29. Tomescu C, Duh FM, Hoh R, Viviani A, Harvill K, et al. (2012) Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers. AIDS 26: 1869–1878.
30. Pancino G, Saez-Cirion A, Scott-Algara D, Paul P, (2010) Natural resistance to HIV infection: lessons learned from HIV-exposed uninfected individuals. J Infect Dis 202 Suppl 3S345–350.
31. Tomescu C, Duh FM, Lanier MA, Kapalko A, Mounzer KC, et al. (2010) Increased plasmacytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users. AIDS 24: 2151–2160.
32. Ravet S, Scott-Algara D, Bonnet E, Tran HK, Tran T, et al. (2007) Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 109: 4296–4305.
33. Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, et al. (2001) Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci U S A 98: 5140–5145.
34. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, et al. (2007) Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 204: 3027–3036.
35. O'Connell KA, Han Y, Williams TM, Siliciano RF, Blankson JN, (2009) Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J Virol 83: 5028–5034.
36. Elemans M, Thiebaut R, Kaur A, Asquith B, (2011) Quantification of the relative importance of CTL, B cell, NK cell, and target cell limitation in the control of primary SIV-infection. PLoS Comput Biol 7: e1001103.
37. Reeves RK, Gillis J, Wong FE, Yu Y, Connole M, et al. (2010) CD16- natural killer cells: enrichment in mucosal and secondary lymphoid tissues and altered function during chronic SIV infection. Blood 115: 4439–4446.
38. Abdel-Motal UM, Gillis J, Manson K, Wyand M, Montefiori D, et al. (2005) Kinetics of expansion of SIV Gag-specific CD8+T lymphocytes following challenge of vaccinated macaques. Virology 333: 226–238.
39. Reeves RK, Gillis J, Wong FE, Johnson RP, (2009) Vaccination with SIVmac239Deltanef activates CD4+T cells in the absence of CD4 T-cell loss. J Med Primatol 38 Suppl 18–16.
40. Giavedoni LD, (2005) Simultaneous detection of multiple cytokines and chemokines from nonhuman primates using luminex technology. Journal of Immunological Methods 301: 89–101.
41. Cline AN, Bess JW, Piatak M, JrLifson JD, (2005) Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 34: 303–312.
42. Hansen SG, Piatak M, JrVentura AB, Hughes CM, Gilbride RM, et al. (2013) Immune clearance of highly pathogenic SIV infection. Nature 502: 100–104.
43. Reeves RK, Evans TI, Gillis J, Johnson RP, (2010) Simian immunodeficiency virus infection induces expansion of alpha4beta7+ and cytotoxic CD56+ NK cells. J Virol 84: 8959–8963.
44. Reeves RK, Evans TI, Gillis J, Wong FE, Kang G, et al. (2012) SIV infection induces accumulation of plasmacytoid dendritic cells in the gut mucosa. J Infect Dis 206: 1462–1468.
45. Estes JD, Harris LD, Klatt NR, Tabb B, Pittaluga S, et al. (2010) Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog 6. DOI:10.1371/journal.ppat.1001052
46. Klatt NR, Funderburg NT, Brenchley JM, (2013) Microbial translocation, immune activation, and HIV disease. Trends Microbiol 21: 6–13.
47. Mortha A, Chudnovskiy A, Hashimoto D, Bogunovic M, Spencer SP, et al. (2014) Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 343: 1249288.
48. Klose CS, Kiss EA, Schwierzeck V, Ebert K, Hoyler T, et al. (2013) A T-bet gradient controls the fate and function of CCR6-RORgammat+ innate lymphoid cells. Nature 494: 261–265.
49. Buonocore S, Ahern PP, Uhlig HH, Ivanov, II, Littman DR, et al. (2010) Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464: 1371–1375.
50. Fuchs A, Colonna M, (2013) Innate lymphoid cells in homeostasis, infection, chronic inflammation and tumors of the gastrointestinal tract. Curr Opin Gastroenterol 29: 581–587.
51. Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, et al. (2005) Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 106: 3366–3369.
52. Alter G, Teigen N, Ahern R, Streeck H, Meier A, et al. (2007) Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis 195: 1452–1460.
53. Choi EI, Reimann KA, Letvin NL, (2008) In vivo natural killer cell depletion during primary simian immunodeficiency virus infection in rhesus monkeys. Journal of Virology 82: 6758–6761.
54. Choi EI, Wang R, Peterson L, Letvin NL, Reimann KA, (2008) Use of an anti-CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques. Immunology 124: 215–222.
55. Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, et al. (1998) Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol 161: 6433–6438.
56. O'Connor GM, Holmes A, Mulcahy F, Gardiner CM, (2007) Natural killer cells from long-term non-progressor HIV patients are characterized by altered phenotype and function. Clin Immunol 124: 277–283.
57. Giavedoni LD, Velasquillo MC, Parodi LM, Hubbard GB, Hodara VL, (2000) Cytokine expression, natural killer cell activation, and phenotypic changes in lymphoid cells from rhesus macaques during acute infection with pathogenic simian immunodeficiency virus. J Virol 74: 1648–1657.
58. Shieh TM, Carter DL, Blosser RL, Mankowski JL, Zink MC, et al. (2001) Functional analyses of natural killer cells in macaques infected with neurovirulent simian immunodeficiency virus. J Neurovirol 7: 11–24.
59. Bostik P, Kobkitjaroen J, Tang W, Villinger F, Pereira LE, et al. (2009) Decreased NK cell frequency and function is associated with increased risk of KIR3DL allele polymorphism in simian immunodeficiency virus-infected rhesus macaques with high viral loads. J Immunol 182: 3638–3649.
60. Gonzalez VD, Falconer K, Michaelsson J, Moll M, Reichard O, et al. (2008) Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin. Clin Immunol 128: 46–56.
61. Marras F, Nicco E, Bozzano F, Di Biagio A, Dentone C, et al. (2013) Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. Proc Natl Acad Sci U S A 110: 11970–11975.
62. Michaelsson J, Long BR, Loo CP, Lanier LL, Spotts G, et al. (2008) Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2. J Infect Dis 197: 117–125.
63. Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, et al. (2011) Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57. J Virol 85: 5949–5960.